Literature DB >> 23372923

Smoking: Is it a risk factor for pulmonary vascular diseases?

Norbert Weissmann1, Friedrich Grimminger, Werner Seeger.   

Abstract

Entities:  

Year:  2012        PMID: 23372923      PMCID: PMC3555409          DOI: 10.4103/2045-8932.105027

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


× No keyword cloud information.
Chronic obstructive pulmonary disease (COPD) summarizes chronic bronchitis and lung emphysema. A major trigger for this disease is cigarette smoking. However, the occurrence and role of pulmonary vascular remodeling and pulmonary hypertension (PH) in COPD is not clarified yet. Although PH and lung vascular remodeling were thought to be infrequent events in COPD, recent clinical data estimate that 30-70% of patients with COPD also have PH.[1] In 50% of COPD patients evaluated for lung transplantation, mean pulmonary arterial pressure was above 25 mmHg.[2] In addition, a much larger portion of COPD patients may be affected by morphological changes of the lung vessels and/or borderline PH.[3-5] In this regard it has recently been stated that “moderate-to-severe PH is not a rare event” in COPD[2] and “numerous studies have shown that the presence of even mild PH is of prognostic relevance in patients with COPD.”[3] Without doubt, late-stage COPD can result in a lack of oxygen, which can trigger pulmonary vascular remodeling, similar to chronic alveolar hypoxia. However, recently it has been proposed that pulmonary vascular alterations are not secondary to lung emphysema development but can even be the driving force of COPD. Indeed, there is increasing evidence that cigarette smoke may have a major direct impact on the pulmonary vasculature, suggesting that PH and subsequent cor pulmonale are not necessarily secondary to hypoxia in patients with COPD.[6-8] This field of research was largely driven by investigations from Joan Barbera's group, who documented that pulmonary vascular remodeling (resembling pulmonary vascular remodeling occurring in PH patients) occurs in smokers who have not yet developed COPD.[5] For detailed investigations of the time course of possible tobacco-smoke induced pulmonary vascular remodeling processes and emphysema development, animal experiments can be helpful. They may decipher 1) whether lung vascular remodeling generally occurs during tobacco smoke exposure, 2) whether it leads to PH, and 3) whether it precedes lung emphysema development. Early studies already clearly showed that tobacco smoke causes vascular remodeling with thickening of the vessel wall, and studies in guinea pigs and recently in mice described that pulmonary vascular remodeling may be observed prior to lung emphysema development.[9-12] An investigation from our group showed that pulmonary vascular remodeling and PH induced by tobacco smoke occur in the absence of hypoxia and precede the development of alveolar destruction and emphysema formation. This study furthermore revealed that emphysema and PH development are not essentially linked but can occur independently—at least in mice. Whereas emphysema development was dependent on the inducible NO synthase (iNOS) in non-bone marrow derived cells, PH was dependent on iNOS in bone marrow-derived cells (Fig. 1).[12] Nevertheless, this study proposed that a vascular iNOS upregulation induced by tobacco smoke, even in the absence of vascular remodeling, can trigger emphysema.
Figure 1

Smoke-induced vascular alterations and emphysema development. A recent study in mice revealed that tobacco smoke-induced vascular remodeling and PH is dependent on iNOS activity in bone marrow-derived cells, whereas lung emphysema development was dependent on iNOS activity in non-bone marrow-derived cells. iNOS inhibition with L-N6-(1-iminoethyl)- lysine (L-NIL) could not only prevent but also reversed established PH and emphysema in mice.[15]

Smoke-induced vascular alterations and emphysema development. A recent study in mice revealed that tobacco smoke-induced vascular remodeling and PH is dependent on iNOS activity in bone marrow-derived cells, whereas lung emphysema development was dependent on iNOS activity in non-bone marrow-derived cells. iNOS inhibition with L-N6-(1-iminoethyl)- lysine (L-NIL) could not only prevent but also reversed established PH and emphysema in mice.[15] Provided that such animal studies also apply to the human situation—which is supported by studies in smokers that have not yet developed COPD, but display pulmonary vascular remodeling—[513] it is clear that tobacco smoke can trigger vascular alterations even without signs of COPD. Such alterations, which can affect biochemical pathways, vascular function, as well as the morphology of the pulmonary vessels,[14] may also—going beyond pulmonary vascular disease—drive emphysema development.[15]
  13 in total

1.  Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice.

Authors:  Michael Seimetz; Nirmal Parajuli; Alexandra Pichl; Florian Veit; Grazyna Kwapiszewska; Friederike C Weisel; Katrin Milger; Bakytbek Egemnazarov; Agnieszka Turowska; Beate Fuchs; Sandeep Nikam; Markus Roth; Akylbek Sydykov; Thomas Medebach; Walter Klepetko; Peter Jaksch; Rio Dumitrascu; Holger Garn; Robert Voswinckel; Sawa Kostin; Werner Seeger; Ralph T Schermuly; Friedrich Grimminger; Hossein A Ghofrani; Norbert Weissmann
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

2.  Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective.

Authors:  Omar A Minai; Ari Chaouat; Serge Adnot
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

3.  Endothelial dysfunction in pulmonary arteries of patients with mild COPD.

Authors:  V I Peinado; J A Barbera; J Ramirez; F P Gomez; J Roca; L Jover; J M Gimferrer; R Rodriguez-Roisin
Journal:  Am J Physiol       Date:  1998-06

4.  Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation.

Authors:  Gabriel Thabut; Gaëlle Dauriat; Jean Baptiste Stern; Damien Logeart; Antoine Lévy; Rolana Marrash-Chahla; Hervé Mal
Journal:  Chest       Date:  2005-05       Impact factor: 9.410

5.  Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD.

Authors:  S Santos; V I Peinado; J Ramírez; T Melgosa; J Roca; R Rodriguez-Roisin; J A Barberà
Journal:  Eur Respir J       Date:  2002-04       Impact factor: 16.671

6.  Cigarette smoke causes physiologic and morphologic changes of emphysema in the guinea pig.

Authors:  J L Wright; A Churg
Journal:  Am Rev Respir Dis       Date:  1990-12

7.  Effect of long-term cigarette smoke exposure on pulmonary vascular structure and function in the guinea pig.

Authors:  J L Wright; A Churg
Journal:  Exp Lung Res       Date:  1991 Nov-Dec       Impact factor: 2.459

Review 8.  Pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  J A Barberà; V I Peinado; S Santos
Journal:  Eur Respir J       Date:  2003-05       Impact factor: 16.671

Review 9.  Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension.

Authors:  Marius M Hoeper; Joan Albert Barberà; Richard N Channick; Paul M Hassoun; Irene M Lang; Alessandra Manes; Fernando J Martinez; Robert Naeije; Horst Olschewski; Joanna Pepke-Zaba; Margaret M Redfield; Ivan M Robbins; Rogério Souza; Adam Torbicki; Michael McGoon
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

10.  Effects of cigarette smoke on endothelial function of pulmonary arteries in the guinea pig.

Authors:  Elisabet Ferrer; Víctor Ivo Peinado; Marta Díez; Josep Lluís Carrasco; Melina Mara Musri; Anna Martínez; Robert Rodríguez-Roisin; Joan Albert Barberà
Journal:  Respir Res       Date:  2009-08-14
View more
  6 in total

1.  Long-term pulmonary vascular consequences of perinatal insults.

Authors:  Kara Goss
Journal:  J Physiol       Date:  2018-08-24       Impact factor: 5.182

Review 2.  Perspective: ambient air pollution: inflammatory response and effects on the lung's vasculature.

Authors:  Gabriele Grunig; Leigh M Marsh; Nafiseh Esmaeil; Katelin Jackson; Terry Gordon; Joan Reibman; Grazyna Kwapiszewska; Sung-Hyun Park
Journal:  Pulm Circ       Date:  2014-03       Impact factor: 3.017

Review 3.  Addressing the challenges of phenotyping pediatric pulmonary vascular disease.

Authors:  Kara N Goss; Allen D Everett; Peter M Mourani; Christopher D Baker; Steven H Abman
Journal:  Pulm Circ       Date:  2017-01-01       Impact factor: 3.017

4.  Smoking Significantly Impacts Persistence Rates in Embolized Pulmonary Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia.

Authors:  Mustafa M Haddad; Emily C Bendel; William S Harmsen; Vivek N Iyer; Sanjay Misra
Journal:  Radiology       Date:  2019-07-30       Impact factor: 11.105

5.  Combined Pulmonary Fibrosis Emphysema: Role of Cigarette Smoking and Pulmonary Hypertension in a Rural Cohort.

Authors:  Rahul Sangani; Andrew Ghio; Stacey Culp; Zalak Patel; Sunil Sharma
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-06-21

Review 6.  Cigarette Smoke Particle-Induced Lung Injury and Iron Homeostasis.

Authors:  Andrew J Ghio; Elizabeth N Pavlisko; Victor L Roggli; Nevins W Todd; Rahul G Sangani
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.